ITGAV and breast carcinoma: It is reported that ITGAV silencing inhibits cell proliferation, invasion and self-renewal of breast cancer cell lines by altering the expression of BCL2 apoptosis regulator (BCL2) and paxillin (PXN) (Cheuk et al., 2020).